The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Barclays Downgrades Glaxo To Underweight

Thu, 16th Jan 2020 09:38

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

BARCLAYS CUTS GLAXOSMITHKLINE TO 'UNDERWEIGHT' (EQUAL WEIGHT) - PRICE TARGET 1650 PENCE

----------

CREDIT SUISSE RAISES GLAXOSMITHKLINE PRICE TARGET TO 1860 (1800) PENCE - 'NEUTRAL'

----------

BARCLAYS RAISES ASTRAZENECA PRICE TARGET TO 8500 (8300) PENCE - 'OVERWEIGHT'

----------

CREDIT SUISSE RAISES ASTRAZENECA PRICE TARGET TO 8500 (8200) PENCE - 'OUTPERFORM'

----------

JEFFERIES CUTS DIAGEO TO 'HOLD' (BUY) - PRICE TARGET 3600 PENCE

----------

JPMORGAN RAISES SEGRO PRICE TARGET TO 855 (775) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES INFORMA PRICE TARGET TO 873 (869) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES BRITISH LAND CO PRICE TARGET TO 630 (605) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS PEARSON PRICE TARGET TO 860 (950) PENCE - 'OVERWEIGHT'

----------

UBS RAISES WPP PRICE TARGET TO 1175 (1125) PENCE - 'BUY'

----------

GOLDMAN REINITIATES VODAFONE WITH 'BUY' - PRICE TARGET 190 PENCE

----------

CREDIT SUISSE CUTS GLENCORE PRICE TARGET TO 300 (310) PENCE - 'OUTPERFORM'

----------

JPMORGAN RAISES BAE SYSTEMS PRICE TARGET TO 715 (700) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES MEGGITT PRICE TARGET TO 730 (685) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

JPMORGAN CUTS UNITE GROUP TO 'UNDERWEIGHT' ('NEUTRAL') - TARGET 1200 PENCE

----------

JPMORGAN CUTS BIG YELLOW TO 'UNDERWEIGHT' (NEUTRAL) - TARGET 1150 (1050) PENCE

----------

JPMORGAN RAISES WORKSPACE GROUP TARGET TO 1220 (1160) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES ST. MODWEN PROPERTIES TARGET TO 530 (490) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES HAMMERSON PRICE TARGET TO 300 (290) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES GREAT PORTLAND PRICE TARGET TO 880 (845) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES GRAINGER PRICE TARGET TO 330 (310) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES DERWENT LONDON TARGET TO 3720 (3500) PENCE - 'UNDERWEIGHT'

----------

JPMORGAN RAISES ASSURA GROUP PRICE TARGET TO 81 (79) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES ELECTROCOMPONENTS TO 'OVERWEIGHT' (NEUTRAL) - TARGET 774 (651) PENCE

----------

BARCLAYS CUTS SPIRENT TO 'UNDERWEIGHT' ('EQUAL WEIGHT') - TARGET 190 (159) PENCE

----------

JPMORGAN RAISES ULTRA ELECTRONICS PRICE TARGET TO 2400 (2200) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES QINETIQ PRICE TARGET TO 360 (340) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES DIPLOMA PRICE TARGET TO 1760 (1730) PENCE - 'NEUTRAL'

----------

JPMORGAN INITIATES PPHE HOTELS WITH 'OVERWEIGHT' - TARGET 2500 PENCE

----------

UBS RAISES ASHMORE GROUP PRICE TARGET TO 527 (480) PENCE - 'NEUTRAL'

----------

CREDIT SUISSE RAISES ASHMORE GROUP PT TO 480 (440) PENCE - 'UNDERPERFORM'

----------

OTHER MAIN MARKET AND AIM

----------

JPMORGAN CUTS INTU PROPERTIES PRICE TARGET TO 25 (29) PENCE - 'UNDERWEIGHT'

----------

JPMORGAN RAISES HELICAL PRICE TARGET TO 475 (450) PENCE - 'NEUTRAL'

----------

BARCLAYS RAISES GAMMA COMMUNICATIONS PRICE TARGET TO 1350 (1250) PENCE - 'OVERWEIGHT'

----------

BARCLAYS CUTS IQE TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 55 (73) PENCE

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.